This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ tranilast,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Allergic Diseases:

    • Tranilast is indicated for the treatment of allergic conditions such as allergic rhinitis (hay fever), allergic conjunctivitis (eye allergies), and allergic asthma. It exerts its effects by inhibiting the release of inflammatory mediators such as histamine, leukotrienes, and prostaglandins from mast cells and other immune cells, thereby reducing allergic symptoms.

  2. Atopic Dermatitis (Eczema):

    • Tranilast may be used in the treatment of atopic dermatitis, a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It helps alleviate symptoms by suppressing inflammation and modulating the immune response in the skin.

  3. Keloids and Hypertrophic Scars:

    • Tranilast has been investigated for its potential role in the prevention and treatment of keloids and hypertrophic scars, which are abnormal types of scar tissue that result from excessive collagen formation during the wound healing process. Tranilast helps inhibit the proliferation of fibroblasts and the production of collagen, thereby reducing scar formation and promoting scar remodeling.

  4. Diabetic Complications:

    • Tranilast may be used in the management of diabetic complications such as diabetic nephropathy (kidney disease) and diabetic retinopathy (eye disease). It exerts protective effects on the kidneys and eyes by inhibiting the accumulation of extracellular matrix proteins, reducing inflammation, and preventing oxidative stress-induced damage.

  5. Interstitial Cystitis (Bladder Pain Syndrome):

    • Tranilast has been investigated as a potential treatment for interstitial cystitis, also known as bladder pain syndrome, a chronic bladder condition characterized by pelvic pain, urinary frequency, and urgency. Tranilast may help alleviate symptoms by reducing inflammation and modulating bladder function.

  6. Atherosclerosis and Cardiovascular Diseases:

    • Tranilast has been studied for its potential anti-atherosclerotic effects and its ability to prevent restenosis (re-narrowing of blood vessels) following angioplasty or stent placement. It may help inhibit the proliferation of smooth muscle cells in blood vessel walls and reduce inflammation, thereby preventing the progression of atherosclerosis and restenosis.

  7. Pulmonary Fibrosis:

    • Tranilast has shown promise in the treatment of pulmonary fibrosis, a progressive lung disease characterized by the formation of scar tissue in the lungs. It may help attenuate fibrosis by inhibiting the activation of fibroblasts and the deposition of collagen in the lung tissue.

  8. Side Effects:

    • Common side effects of tranilast may include gastrointestinal disturbances (such as nausea, diarrhea, and dyspepsia), dizziness, headache, and skin reactions. Rare but more serious side effects may include hepatotoxicity (liver damage) and hypersensitivity reactions. It's important to inform a healthcare provider of any adverse reactions experienced while taking tranilast.
;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of tranilast,(prescription) On Probiotics

Rank Probiotic Impact

Bacteria Impacted by tranilast,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Dorea genus Decreases
0 1 Roseburia genus Decreases
0 1 Ruminococcus genus Decreases
0 1 Agathobacter genus Decreases
0 1 Bacteroides genus Decreases
0 1 Clostridioides genus Decreases
0 1 Eggerthella genus Decreases
0 1 Fusobacterium genus Decreases
0 1 Lachnospira genus Decreases
0 1 Lacrimispora genus Decreases
0 1 Odoribacter genus Decreases
0 1 Streptococcus genus Decreases
0 1 Thomasclavelia genus Decreases
1 0 Eggerthella lenta species Decreases
1 0 Streptococcus salivarius species Decreases
1 0 Lachnospira eligens species Decreases
1 0 Agathobacter rectalis species Decreases
1 0 Lacrimispora saccharolytica species Decreases
1 0 Odoribacter splanchnicus species Decreases
1 0 Fusobacterium nucleatum species Decreases
1 0 Clostridioides difficile species Decreases
1 0 Dorea formicigenerans species Decreases
1 0 Roseburia intestinalis species Decreases
1 0 Thomasclavelia ramosa species Decreases
1 0 Bacteroides xylanisolvens species Decreases
1 0 Ruminococcus bromii species Decreases
0 1 Fusobacterium nucleatum subsp. nucleatum subspecies Decreases

Impact of tranilast,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 2 0.3 5.67
Age-Related Macular Degeneration and Glaucoma 1.1 1.1
Allergic Rhinitis (Hay Fever) 1.2 0.3 3
Allergies 1 0.9 0.11
Allergy to milk products 0.6 0.3 1
Alopecia (Hair Loss) 0.6 0.6
Alzheimer's disease 1.8 2.5 -0.39
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.2 0.3 3
Ankylosing spondylitis 1.4 1.2 0.17
Anorexia Nervosa 0.6 2.3 -2.83
Antiphospholipid syndrome (APS) 0.3 0.3
Asthma 3.4 1.1 2.09
Atherosclerosis 0.9 0.7 0.29
Atrial fibrillation 2 0.5 3
Autism 3.4 3.4 0
Autoimmune Disease 0.3 0.5 -0.67
Barrett esophagus cancer 0.3 0.3 0
benign prostatic hyperplasia 0.3 -0.3
Biofilm 0.4 0.4
Bipolar Disorder 0.9 1.1 -0.22
Brain Trauma 0.3 1.1 -2.67
Breast Cancer 0.1 0.1
Cancer (General) 0.6 0.6
Carcinoma 2.4 1.5 0.6
Celiac Disease 0.9 1.7 -0.89
Cerebral Palsy 0.6 1.1 -0.83
Chronic Fatigue Syndrome 2 1.9 0.05
Chronic Kidney Disease 1.2 1 0.2
Chronic Lyme 0.1 0.8 -7
Chronic Obstructive Pulmonary Disease (COPD) 1 1.4 -0.4
Chronic Urticaria (Hives) 0.3 0.3
Coagulation / Micro clot triggering bacteria 0.3 1.1 -2.67
Cognitive Function 1.5 1.1 0.36
Colorectal Cancer 2.5 1.1 1.27
Constipation 0.9 0.5 0.8
Coronary artery disease 0.9 1.3 -0.44
COVID-19 2.3 3.8 -0.65
Crohn's Disease 3 3.1 -0.03
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 0.8 -0.8
deep vein thrombosis 0.1 1.4 -13
Denture Wearers Oral Shifts 0.8 0.8
Depression 3.7 2.8 0.32
Dermatomyositis 0.3 0.3
Eczema 0.6 0.7 -0.17
Endometriosis 1.2 1.4 -0.17
Eosinophilic Esophagitis 0.3 0.3 0
Epilepsy 0.9 0.3 2
erectile dysfunction 0.6 0.6
Fibromyalgia 1.4 0.3 3.67
Functional constipation / chronic idiopathic constipation 1.5 1.1 0.36
gallstone disease (gsd) 0.9 0.8 0.13
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.4 0.6 -0.5
Generalized anxiety disorder 1.2 0.6 1
Glioblastoma 0.3 -0.3
Gout 0.9 0.9
Graves' disease 0.6 2 -2.33
Gulf War Syndrome 0.3 0.3
Halitosis 1 0.3 2.33
Hashimoto's thyroiditis 2 0.6 2.33
Heart Failure 1.3 1.1 0.18
hemorrhagic stroke 0.9 0.9
Hidradenitis Suppurativa 1.2 1.2
High Histamine/low DAO 0.5 0.3 0.67
hypercholesterolemia (High Cholesterol) 0.3 0.3
hyperglycemia 0.4 0.3 0.33
hypertension (High Blood Pressure 1.7 2 -0.18
Hypothyroidism 0.3 -0.3
Hypoxia 0.9 0.9
IgA nephropathy (IgAN) 1.5 0.8 0.88
Inflammatory Bowel Disease 2.2 2.9 -0.32
Insomnia 1.6 2 -0.25
Intelligence 0.3 0.3
Intracranial aneurysms 0.9 0.9
Irritable Bowel Syndrome 2.1 1.7 0.24
ischemic stroke 0.9 1.1 -0.22
Liver Cirrhosis 3.6 2.3 0.57
Long COVID 2.1 3.2 -0.52
Low bone mineral density 0.8 -0.8
Lung Cancer 0.9 -0.9
Mast Cell Issues / mastitis 0.4 0.3 0.33
ME/CFS with IBS 0.3 0.3 0
ME/CFS without IBS 1.1 0.9 0.22
membranous nephropathy 0.3 0.3
Menopause 0.3 0.5 -0.67
Metabolic Syndrome 2.9 2.6 0.12
Mood Disorders 3.1 2.5 0.24
multiple chemical sensitivity [MCS] 0.7 0.7
Multiple Sclerosis 2.6 2 0.3
Multiple system atrophy (MSA) 0.3 -0.3
myasthenia gravis 0.3 0.5 -0.67
neuropathic pain 0.3 1.3 -3.33
Neuropathy (all types) 0.6 0.7 -0.17
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.9 1.9 0.53
NonCeliac Gluten Sensitivity 0.6 0.3 1
Obesity 3.1 3.6 -0.16
obsessive-compulsive disorder 1 1.7 -0.7
Osteoarthritis 0.6 0.9 -0.5
Osteoporosis 1.4 1.2 0.17
pancreatic cancer 0.7 0.3 1.33
Parkinson's Disease 2.2 3.3 -0.5
Polycystic ovary syndrome 1.7 1.7 0
primary biliary cholangitis 0.9 0.6 0.5
Primary sclerosing cholangitis 0.9 0.3 2
Psoriasis 0.6 1 -0.67
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.7 2.2 0.23
Rosacea 0.3 0.5 -0.67
Schizophrenia 2 1.4 0.43
scoliosis 0.6 -0.6
Sjögren syndrome 0.6 1.2 -1
Sleep Apnea 1.5 1.4 0.07
Slow gastric motility / Gastroparesis 0.6 0.6
Small Intestinal Bacterial Overgrowth (SIBO) 0.9 0.9
Stress / posttraumatic stress disorder 1.7 1.3 0.31
Systemic Lupus Erythematosus 1.4 1.6 -0.14
Tic Disorder 0.9 0.6 0.5
Tourette syndrome 0.9 0.3 2
Type 1 Diabetes 0.9 1.7 -0.89
Type 2 Diabetes 3.2 2.3 0.39
Ulcerative colitis 1.6 1.5 0.07
Unhealthy Ageing 1.9 1 0.9
Vitiligo 1.2 1.2

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]